A unified nanopore-based approach for direct telomere sequencing and genetic diagnosis in inherited bone marrow failure syndromes

S Shota Kato H Hirohisa Yajima (2The University of Tokyo, Department of Neurosurgery, Graduate School of Medicine, Tokyo, Japan) A Aiko Sato-Otsubo (6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan) W Wataru Nakamura M Masahiro Sugawa (3National Cancer Center Research Institute, Division of Genome Analysis Platform Development, Tokyo, Japan) J Junji Ikeda (1Yokohama City University, Department of Pediatrics, Yokohama, Japan) S Shin-Ichi Tsujimoto (5Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan) M Miwako Toyohara (1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan) N Nao Takasugi (1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan) M Moe Hidaka (1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan) Y Yasuo Kubota (4Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan) K Kentaro Watanabe (6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan) Y Yuichi Shiraishi M Motohiro Kato (6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)

Abstract

Abstract Introduction: Telomeres are repetitive sequences located at the ends of chromosomes. Impaired telomere maintenance in telomere biology disorders, including dyskeratosis congenita (DC), is caused by pathogenic alterations in several genes, such as DKC1, TINF2, TERC, and TERT, resulting in bone marrow failure and various systemic manifestations. Therefore, telomere length measurement is useful for the diagnosis of inherited bone marrow failure syndromes (IBMFSs), along with genetic testing. However, telomere length measurement and genetic analysis are performed through separate assays: telomere length is typically evaluated using flow cytometry with fluorescent in situ hybridization method or quantitative PCR, whereas genetic abnormalities are generally detected through next-generation sequencing approaches. Herein, we established an analytical pipeline for diagnosis of IBMFSs through simultaneous direct telomere sequencing and genetic analysis by targeted adaptive sampling long-read sequencing (TAS-LRS), a computational targeted sequencing technique using a nanopore sequencer. Methods: Ten peripheral blood or bone marrow samples were analyzed: two patients with DC, one with Fanconi anemia, six with idiopathic aplastic anemia, and one healthy participant (age, 1.4–33.5 years). DNA was mildly fragmented, targeting an N50 of ~15,000 bp. Our TAS-LRS pipeline consisted of two modules: direct telomere sequencing and genomic diagnosis of IBMFSs. The direct telomere sequencing module enriched telomeric/subtelomeric regions, then identified reads that were aligned to the subtelomeric regions of the T2T-CHM13 and also contained the canonical telomere repeat (TTAGGG) or telomere variant repeats (TVRs; TGAGGG, TCAGGG, and TTGGGG) in more than 80% of the contiguous sequence extending from the subtelomeric regions. The telomere lengths of these reads were calculated. The genomic diagnosis module enriched 188 genes associated with IBMFSs, and single-nucleotide variants, small insertions/deletions, structural variations, and copy number variations were identified. TAS-LRS was performed using a GridION sequencer and R10.4 flowcells (Oxford Nanopore Technologies, OX, UK). Results: Mean depth of on-target regions was 17.1× in median (10.6×–25.9×). N50 of on-target regions was 14,832 bp in median (13,328–18,132 bp) with no statistical significance between those with and without DC (average, 15,230 bp vs. 15,194 bp, P = 0.96). The direct telomere sequencing module revealed that estimated telomere length was significantly lower in samples with DC than those without DC (average, 3,856 vs. 6,249 bp, P < 1×10-15). Regarding telomere composition, the DC group exhibited a significantly lower proportion of canonical telomere repeats (average, 82.9% vs. 87.8%, P < 1×10-15) and a significantly higher proportion of TVRs (average, 8.2% vs. 6.1%, P = 1.0×10-6) compared to the non-DC group. These observations were consistent with the known localization of TVRs predominantly in the proximal regions of telomeres and the progressive shortening of telomeres from the distal ends. In the eight samples without DC, telomere length demonstrated an age-associated shortening trend, with a mild negative correlation (r = -0.59). The genomic diagnosis module identified a pathogenic variant of TINF2 in a patient with DC. Also, compound heterozygous variants of FANCG were detected in the patient with Fanconi anemia: a nonsense variant and a complex structural variation resulting in complete deletion of FANCG.Conclusions: This study suggested the validity of telomere length measurement and the capability to detect telomere shortening in patients with DC using the direct telomere sequencing module of our TAS-LRS pipeline. Furthermore, the genomic diagnosis module successfully identified pathogenic variants associated with IBMFSs, with the advantage of long-read sequencing particularly evident in detecting complex structural variations. Collectively, this study demonstrated the utility of TAS-LRS as a comprehensive diagnostic approach for IBMFS through simultaneous direct telomere sequencing and genetic analysis.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 4990-4990
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (14)

S

Shota Kato

H

Hirohisa Yajima

2The University of Tokyo, Department of Neurosurgery, Graduate School of Medicine, Tokyo, Japan

A

Aiko Sato-Otsubo

6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

W

Wataru Nakamura

M

Masahiro Sugawa

3National Cancer Center Research Institute, Division of Genome Analysis Platform Development, Tokyo, Japan

J

Junji Ikeda

1Yokohama City University, Department of Pediatrics, Yokohama, Japan

S

Shin-Ichi Tsujimoto

5Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

M

Miwako Toyohara

1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan

N

Nao Takasugi

1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan

M

Moe Hidaka

1The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan

Y

Yasuo Kubota

4Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

K

Kentaro Watanabe

6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Y

Yuichi Shiraishi

M

Motohiro Kato

6Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan